Neoadjuvant Therapy of Pembrolizumab + Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer (EAST ENERGY)

NCT04040361 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Lung Cancer Stage IB
Non-small Cell Lung Cancer Stage II
Non-small Cell Lung Cancer Stage ⅢA

Interventions

DRUG: Pembrolizumab
DRUG: Ramucirumab
PROCEDURE: Surgery

Sponsor

Masahiro Tsuboi

Collaborators

[object Object]
[object Object]